Phenex Pharmaceuticals AG

There have been numerous deals centered on metabolic dysfunction-associated steatohepatitis (MASH) over roughly the past decade, but the 14 May deal in which GSK acquired Boston Pharmaceuticals’ Phase

October ended and November began with the announcement of three new venture capital and equity funds with more than $1.3bn for health care, life science and biopharmaceutical investments. Revelation P

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. OrsoBio Splurges With Four Concurrent L

Gilead Sciences Inc. unveiled Phase II data for its farnesoid X receptor (FXR) agonist GS-9674 in non-alcoholic steatohepatitis (NASH) that raise doubts for its promise in that indication compared to